Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lineage Cell Therapeutics Inc

0.9853
-0.0347-3.40%
Post-market: 0.98540.0001+0.01%19:29 EDT
Volume:2.01M
Turnover:2.00M
Market Cap:225.00M
PE:-12.83
High:1.04
Open:1.01
Low:0.9600
Close:1.02
Loading ...

Lineage Cell Therapeutics Inc. Concluded Annual Shareholder Meeting

Reuters
·
03 Jul

Lineage Cell Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Jun

BRIEF-Opregen® 36-Month Visual Acuity Results Featured At Clinical Trials At The Summit 2025

Reuters
·
23 Jun

Lineage Cell Therapeutics Announces Promising 36-Month Results from OpRegen Cell Therapy Trial for Geographic Atrophy in AMD Patients

Reuters
·
23 Jun

Analysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Lineage Therap (LCTX)

TIPRANKS
·
23 Jun

Lineage Cell Therapeutics Inc. Appoints Baker Tilly as New Auditor Following Merger with Moss Adams

Reuters
·
10 Jun

Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Apellis Pharmaceuticals (APLS)

TIPRANKS
·
23 May

Lineage Cell Therapeutics Inc. to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Reuters
·
14 May

BRIEF-Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update

Reuters
·
14 May

Lineage Cell Therapeutics Reports Q1 2025 Financial Results: Revenues Rise to $1.5M, Net Loss Decreases to $4.1M, EPS Improves to $0.02

Reuters
·
14 May

Press Release: Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Dow Jones
·
01 May

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Business Wire
·
22 Apr

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Business Wire
·
21 Apr

Maxim Group Reaffirms Their Buy Rating on Lineage Therap (LCTX)

TIPRANKS
·
05 Apr

Lineage Cell Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
14 Mar

B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating

MT Newswires Live
·
14 Mar

Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies

TIPRANKS
·
12 Mar

Q4 2024 Lineage Cell Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
11 Mar

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
11 Mar

Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com
·
11 Mar